Previous studies have demonstrated that budesonide is effective for inducing remission of Crohn's disease. Four double-blind, placebo-controlled trials were conducted with identical protocols in which patients with Crohn's Disease, and medically induced remission, received a treatment of oral budesonide for twelve months. Results showed that budesonide taken at six mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse.

"Long-term treatment with budesonide is well-tolerated and the frequency and types of adverse events are similar to placebo," states lead researcher William J. Sandborn, MD. "Safety of a long-term medication is obviously important, but how well a patient tolerates their medication is also important and can affect patient adherence to therapy."

Crohn's disease is a long-term disease that results from inflammation of the digestive tract. It is a debilitating sickness, even for patients who are classified as having mild to moderate disease. Currently, there are no treatment options available that prevents recurrence of symptoms.

"As stated, this disease is recurring in nature, so extending the time a patient can be symptom-free or with diminished symptoms is an important feature of treatment. Budesonide capsules are a treatment option for Crohn's disease that has been shown in studies not only to be very effective in relieving symptoms, but also in extending the time before patients experience a recurrence."

MEDICA.de; Source: Blackwell Publishing Ltd.